Who
Denise P. Carter
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Quoin Pharmaceuticals.
In numbers
- Trades disclosed
- 17
- Buys
- 4
- Sells
- 0
- Bought
- $479K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 26 Oct 2023
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $100K20,490 at $4.88 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —10,245 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —10,245 | filing |
| 31 Aug 2026filed 1 Sep 2026 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $100K20,490 at $4.88 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —318,750 at $0.00 | filing |
| 4 Feb 2026filed 6 Feb 2026 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —318,750 at $0.00 | filing |
| 29 May 2025filed 13 Jun 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,857 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,039 at $0.00 | filing |
| 23 Dec 2024filed 27 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —555,556 | filing |
| 23 Dec 2024filed 27 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —555,556 | filing |
| 23 Dec 2024filed 27 Dec 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $250K555,556 at $0.45 | filing |
| 9 Dec 2024filed 10 Dec 2024 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —536,609 at $0.00 | filing |
| 4 Sep 2024filed 5 Sep 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $6,6198,825 at $0.75 | filing |
| 4 Sep 2024filed 5 Sep 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $18K22,988 at $0.80 | filing |
| 3 Sep 2024filed 5 Sep 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $1,1481,822 at $0.63 | filing |
| 3 Sep 2024filed 5 Sep 2024 | QNRX Quoin PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $2,7064,100 at $0.66 | filing |
| 26 Oct 2023filed 30 Oct 2023 | QNRX Quoin Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,966 at $0.00 | filing |
News
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Raised to "Sell" at Wall Street ZenQNRX · dailypolitical.com · 18 Oct 2026
0 headlines in the last 90 days name Denise P. Carter; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.